Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)

In by ECIR

Locations
St. Augustine
Condition
Heart Failure

Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)

  • This field is for validation purposes and should be left unchanged.
clinicaltrials.gov

Eligibility

Inclusion Criteria

– Patients ≥40 years old
– Diagnosis of symptomatic heart failure, class II-IV HF
– LVEF >40%
– Elevated NT-pro BNP levels

Exclusion Criteria

– currently on an SGLT-2 inhibitor or intolerant to one
– T1DM
– eGFR <25 mL/min - SBP <95 or >160
– MI, unstable angina, stroke, TIA, PCI, CABG, ablation, or valve repair/replacement within 12 weeks prior to enrollment.
– BMI >50 kg/m2

Back to Current Studies